Literature DB >> 25385446

Interethnic differences in pharmacokinetics of antibacterials.

Danny Tsai1, Janattul-Ain Jamal, Joshua S Davis, Jeffrey Lipman, Jason A Roberts.   

Abstract

BACKGROUND: Optimal antibacterial dosing is imperative for maximising clinical outcome. Many factors can contribute to changes in the pharmacokinetics of antibacterials to the extent where dose adjustment may be needed. In acute illness, substantial changes in important pharmacokinetic parameters such as volume of distribution and clearance can occur for certain antibacterials. The possibility of interethnic pharmacokinetic differences can further complicate attempts to design an appropriate dosing regimen. Factors of ethnicity, such as genetics, body size and fat distribution, contribute to differences in absorption, distribution, metabolism and elimination of drugs. Despite extensive previous work on the altered pharmacokinetics of antibacterials in some patient groups such as the critically ill, knowledge of interethnic pharmacokinetic differences for antibacterials is limited.
OBJECTIVES: This systematic review aims to describe any pharmacokinetic differences in antibacterials between different ethnic groups, and discuss their probable mechanisms as well as any clinical implications.
METHODS: We performed a structured literature review to identify and describe available data of the interethnic differences in the pharmacokinetics of antibacterials.
RESULTS: We found 50 articles that met our inclusion criteria and only six of these compared antibacterial pharmacokinetics between different ethnicities within the same study. Overall, there was limited evidence available. We found that interethnic pharmacokinetic differences are negligible for carbapenems, most β-lactams, aminoglycosides, glycopeptides, most fluoroquinolones, linezolid and daptomycin, whereas significant difference is likely for ciprofloxacin, macrolides, clindamycin, tinidazole and some cephalosporins. In general, subjects of Asian ethnicity achieve drug exposures up to two to threefold greater than Caucasian counterparts for these antibacterials. This difference is caused by a comparatively lower volume of distribution and/or drug clearance.
CONCLUSION: Interethnic pharmacokinetic differences of antibacterials are likely; however, the clinical relevance of these differences is unknown and warrants further research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25385446     DOI: 10.1007/s40262-014-0209-3

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  221 in total

Review 1.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

2.  Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Authors:  Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora
Journal:  Int J Antimicrob Agents       Date:  2009-01-15       Impact factor: 5.283

3.  Body weight, race and climate.

Authors:  D F ROBERTS
Journal:  Am J Phys Anthropol       Date:  1953-12       Impact factor: 2.868

Review 4.  Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.

Authors:  Zeqi Huang; Thao Ung
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

5.  Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.

Authors:  Qing-tao Zhou; Bei He; Chao Zhang; Suo-di Zhai; Zhen-ying Liu; Jie Zhang
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

6.  Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects.

Authors:  S G Ganiswarna; P F Wilmana; R Setiabudy; V S Ringoringo
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-02

7.  Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.

Authors:  N Maki; A Ohkuchi; Y Tashiro; M R Kim; M Le; T Sakamoto; S Matsubara; Y Hakamata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-06       Impact factor: 3.267

8.  Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration.

Authors:  S J Hosseine; R Farid; M R Ghalighi; J Feely
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

9.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

10.  P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

Authors:  Jurjen S Lagas; Rolf W Sparidans; Robert A B van Waterschoot; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

View more
  12 in total

1.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

2.  Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Authors:  Danny Tsai; Penelope Stewart; Rajendra Goud; Stephen Gourley; Saliya Hewagama; Sushena Krishnaswamy; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.

Authors:  Mohd H Abdul-Aziz; Azrin N Abd Rahman; Mohd-Basri Mat-Nor; Helmi Sulaiman; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Christine E Staatz
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

4.  A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.

Authors:  Xiaohong Wang; Na Liu; Yudong Wei; Shuang Zhang; Haiyan Li; Bei Yan; Munjal Patel; Hui Wang; Keith E Boundy; Francheska Colon-Gonzalez; Yanqiao Zang; Xumin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

6.  Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.

Authors:  Dong-Hwan Lee; Yong Kyun Kim; Kyubok Jin; Myoung Joo Kang; Young-Don Joo; Yang Wook Kim; Young Soo Moon; Jae-Gook Shin; Sungmin Kiem
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial.

Authors:  Yanxiong Mao; Lan Chen; Ting He; Jing Li; Aiping Zou; Feng Li; Fei Chen; Bo Fan; Weihao Ni; Wei Xiao; Huimin You; Wenjiang Fu
Journal:  BMJ Open       Date:  2022-07-08       Impact factor: 3.006

8.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

Review 9.  Macrolides: From Toxins to Therapeutics.

Authors:  Kiersten D Lenz; Katja E Klosterman; Harshini Mukundan; Jessica Z Kubicek-Sutherland
Journal:  Toxins (Basel)       Date:  2021-05-12       Impact factor: 4.546

10.  Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.

Authors:  Christina König; Anna Both; Holger Rohde; Stefan Kluge; Otto R Frey; Anka C Röhr; Dominic Wichmann
Journal:  Antibiotics (Basel)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.